NANOGEN INC
Research NANOGEN INC (NGEN) on Bullrun: market cap USD 184.09M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNGEN
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 184.09M
- Financial periodQ2 2026
- RevenueCAD 0
- Net income-CAD 29.22M
- Free cash flow-CAD 5.73M
Valuation Snapshot
latest market cap is USD 184.09M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 44.12M | -CAD 19.50M | n/a | -0.61 | CAD 22.07M | CAD 8.37K | CAD 3.48M |
| FY2024 | CAD 0 | -CAD 24.25M | -CAD 16.84M | n/a | -0.36 | CAD 17.27M | CAD 105.60K | CAD 2.58M |
| FY2023 | CAD 0 | -CAD 22.38M | -CAD 11.44M | n/a | -0.38 | CAD 11.66M | CAD 197.19K | -CAD 2.01M |
| FY2022 | CAD 0 | -CAD 20.72M | -CAD 17.81M | n/a | -0.39 | CAD 22.45M | CAD 283.46K | CAD 13.46M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 184.09M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 446.04M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 153.33M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 121.39M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 69.83M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 98.38M | n/a | n/a | n/a |
About NANOGEN INC
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NANOGEN INC's market cap?
NANOGEN INC's market capitalization is USD 184.09M.
What does NANOGEN INC do?
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp.